Limits...
CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J - PLoS ONE (2013)

Bottom Line: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate.Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC.Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Tumor Surgery, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, China.

ABSTRACT

Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis.

Methods: A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software.

Results: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95%CI 0.54-0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95%CI 0.52-0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95%CI 1.01-1.23, P = 0.03), 1.31 (95%CI 1.06-1.63, P = 0.01) and 1.24 (95%CI 1.08-1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters.

Conclusion: Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

Show MeSH

Related in: MedlinePlus

CD133 expression and 5-year DFS rate.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3569427&req=5

pone-0056380-g003: CD133 expression and 5-year DFS rate.

Mentions: The relationship between CD133 expression and the risk of CRC was illustrated in Figure 2–3. Fifteen reports including a total of 2297 patients in regard to the association of CD133 and 5-year OS rate could be obtained from published information, whereas for 5 studies (647 patients in all) information for the correlation of CD133 with 5-year DSF rate could be extracted from the published articles (Table 1). CD133 overexpression was statistically significantly associated with poor 5-year OS rate in either a random-effects model (Figure 2. RR = 0.67, 95% CI = 0.54–0.82, P <0.01) or a fixed-effects model (data not showed). 5-year OS rate was 0.67-fold lower in CD133-positive patients(P<0.01). Furthermore, slight difference had been found in 5-year DSF rate between CD133-high and CD133-low groups assuming a random-effects model (Figure 3. RR = 0.71, 95% CI = 0.52–0.96, P  = 0.03).


CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.

Chen S, Song X, Chen Z, Li X, Li M, Liu H, Li J - PLoS ONE (2013)

CD133 expression and 5-year DFS rate.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3569427&req=5

pone-0056380-g003: CD133 expression and 5-year DFS rate.
Mentions: The relationship between CD133 expression and the risk of CRC was illustrated in Figure 2–3. Fifteen reports including a total of 2297 patients in regard to the association of CD133 and 5-year OS rate could be obtained from published information, whereas for 5 studies (647 patients in all) information for the correlation of CD133 with 5-year DSF rate could be extracted from the published articles (Table 1). CD133 overexpression was statistically significantly associated with poor 5-year OS rate in either a random-effects model (Figure 2. RR = 0.67, 95% CI = 0.54–0.82, P <0.01) or a fixed-effects model (data not showed). 5-year OS rate was 0.67-fold lower in CD133-positive patients(P<0.01). Furthermore, slight difference had been found in 5-year DSF rate between CD133-high and CD133-low groups assuming a random-effects model (Figure 3. RR = 0.71, 95% CI = 0.52–0.96, P  = 0.03).

Bottom Line: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate.Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC.Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Tumor Surgery, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou, China.

ABSTRACT

Objective: CD133 has recently been reported as a marker of cancer stem-like cells in colorectal cancer (CRC). However, its predictive value in CRC still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133 and clinicopathological features and the outcome of CRC patients by performing a meta-analysis.

Methods: A comprehensive literature search for relevant studies published up to December 2012 was performed using PubMed, MEDLINE and ISI Web of Science. Only articles in which CD133 antigen was detected in situ localisation by immunohistochemical staining were included. This meta-analysis was done using RevMan 4.2 software.

Results: We found that a total of 15 studies involving 810 CD133-high and 1487 CD133-low patients met the inclusion criteria for the analysis of 5-year overall survival (OS) rate. In a random-effects model, the results showed that CD133-high expression in colorectal cancer was an independent prognostic marker correlating with both OS rate (RR = 0.67, 95%CI 0.54-0.82, P<0.01) and disease free survival (DFS) rate (RR = 0.71, 95%CI 0.52-0.96, P = 0.03). CD133-high expression was also associated with more T3,4 tumor invasion, N positive and vascular invasion cases, corresponding to a risk difference of 1.12 (95%CI 1.01-1.23, P = 0.03), 1.31 (95%CI 1.06-1.63, P = 0.01) and 1.24 (95%CI 1.08-1.41, P<0.01), respectively. However, when types of histology, lymphatic invasion and distant metastasis were considered, CD133 overexpression was not significantly related with these clinicopathological parameters.

Conclusion: Our meta-analysis results suggest that CD133 is an efficient prognostic factor in CRC. Higher CD133 expression is significantly associated with poorer clinical outcome and some clinicopathological factors such as T category, N category and vascular invasion in CRC patients.

Show MeSH
Related in: MedlinePlus